Levi & Korsinsky probes Dr. Reddy’s after ₹2.4 billion semaglutide provision

The law firm said RDY shares fell about 9% on July 22, 2026 after the company reported a Q1 FY27 earnings miss and disclosed out-of-spec semaglutide batches.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.